DK1597239T3 - Polymorf af {6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3E) - Google Patents

Polymorf af {6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3E)

Info

Publication number: DK1597239T3
Authority: DK; Denmark
Prior art keywords: quinazolin; ethoxy; methoxy; bis; polymorph
Prior art date: 2003-02-17

Application number

DK04710031T

Other languages

English (en)

Other versions

DK1597239T4 (da

Inventor

Andre Gerard Bubendorf

Michael Hennig

Pirmin Hidber

Goesta Rimmler

Franziska Rohrer

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-17

Filing date

2004-02-11

Publication date

2008-12-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32842701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1597239(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-02-11 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2008-12-08 Application granted granted Critical

2008-12-08 Publication of DK1597239T3 publication Critical patent/DK1597239T3/da

2022-09-26 Publication of DK1597239T4 publication Critical patent/DK1597239T4/da

Links

-1 2-methoxy-ethoxy Chemical group 0.000 title 1
GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 abstract 3
206010028980 Neoplasm Diseases 0.000 abstract 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK04710031.8T 2003-02-17 2004-02-11 Polymorf af {6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3e) DK1597239T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP03003587		2003-02-17
PCT/EP2004/001244 WO2004072049A1 (en)	2003-02-17	2004-02-11	Polymorph of {6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3e)

Publications (2)

Publication Number	Publication Date
DK1597239T3 true DK1597239T3 (da)	2008-12-08
DK1597239T4 DK1597239T4 (da)	2022-09-26

Family

ID=32842701

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04710031.8T DK1597239T4 (da)	2003-02-17	2004-02-11	Polymorf af {6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3e)

Country Status (24)

Country	Link
US (1)	US7148231B2 (da)
EP (1)	EP1597239B2 (da)
JP (1)	JP4456079B2 (da)
KR (1)	KR100797430B1 (da)
CN (1)	CN100506803C (da)
AT (1)	ATE408605T1 (da)
AU (1)	AU2004212067C1 (da)
BR (1)	BRPI0407520A (da)
CA (1)	CA2514977C (da)
CO (1)	CO5601019A2 (da)
DE (1)	DE602004016628D1 (da)
DK (1)	DK1597239T4 (da)
ES (1)	ES2314373T5 (da)
HR (1)	HRP20050707B1 (da)
IL (1)	IL169975A (da)
MX (1)	MXPA05008598A (da)
NO (1)	NO330781B1 (da)
NZ (1)	NZ541500A (da)
PL (1)	PL225428B1 (da)
PT (1)	PT1597239E (da)
RU (1)	RU2376294C2 (da)
SI (1)	SI1597239T2 (da)
WO (1)	WO2004072049A1 (da)
ZA (1)	ZA200506339B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5747498A (en)	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
US7625911B2 (en) *	2005-01-12	2009-12-01	Mai De Ltd.	Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
EP2436381A1 (en)	2006-06-27	2012-04-04	Sandoz AG	Crystallization of hydrohalides of pharmaceutical compounds
EP2054393A1 (en)	2006-07-28	2009-05-06	Synthon B.V.	Crystalline erlotinib
US8372856B2 (en)	2006-10-27	2013-02-12	Synthon Bv	Hydrates of erlotinib hydrochloride
ES2573931T3 (es)	2007-02-21	2016-06-13	Natco Pharma Limited	Nuevos polimorfismos de clorhidrato de erlotinib y método de preparación
KR101441930B1 (ko) *	2007-04-04	2014-09-19	시플라 리미티드	에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법
EP2218713A1 (en)	2007-08-17	2010-08-18	Hetero Drugs Limited	Erlotinib hydrochloride polymorph Form A substantially free of polymorph Form B
WO2009025875A1 (en) *	2007-08-23	2009-02-26	Plus Chemicals Sa	Stable formulations of crystalline erlotinib hcl
US20090124642A1 (en) *	2007-08-23	2009-05-14	Augusto Canavesi	Crystalline forms of Erlotinib HCI and formulations thereof
US20100004449A1 (en) *	2008-07-07	2010-01-07	Plus Chemicals Sa	Crystalline forms of erlotinib base and erlotinib hcl
WO2010040212A1 (en) *	2008-10-08	2010-04-15	Apotex Pharmachem Inc.	Processes for the preparation of erlotinib hydrochloride
EP2213281A1 (en)	2009-02-02	2010-08-04	Ratiopharm GmbH	Pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
WO2010109443A1 (en)	2009-03-26	2010-09-30	Ranbaxy Laboratories Limited	Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
WO2011058525A2 (en)	2009-11-12	2011-05-19	Ranbaxy Laboratories Limited	Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
CN101987834B (zh) *	2010-06-13	2012-07-18	信泰制药（苏州）有限公司	一种结晶形态的盐酸埃罗替尼及其制备方法
AU2011298167B2 (en)	2010-07-23	2015-11-26	Generics [Uk] Limited	Pure erlotinib
WO2012150606A2 (en)	2011-05-03	2012-11-08	Cadila Healthcare Limited	A process for preparing stable polymophic form of erlotinib hydrochloride
US9593083B2 (en)	2012-09-04	2017-03-14	Shilpa Medicare Limited	Crystalline erlotinib hydrochloride process
WO2014118737A1 (en)	2013-01-31	2014-08-07	Ranbaxy Laboratories Limited	Erlotinib salts
CN103333124B (zh) *	2013-05-28	2015-03-25	埃斯特维华义制药有限公司	一种制备盐酸厄洛替尼晶型f的方法
WO2016082879A1 (en) *	2014-11-27	2016-06-02	Synthon B.V.	Pharmaceutical composition comprising erlotinib hydrochloride
RU2610337C1 (ru) *	2015-12-10	2017-02-09	Индивидуальный предприниматель Михайлов Олег Ростиславович	Кристаллическая β-модификация N-(3-этинилфенил)-6,7-бис(2 метоксиэтокси)хиназолин-4-амин гидрохлорида, способ её получения и фармацевтическая композиция на её основе
JP2019059685A (ja) *	2017-09-26	2019-04-18	日本化薬株式会社	エルロチニブを有効成分とする医薬錠剤
JP2020090456A (ja) *	2018-12-05	2020-06-11	日本化薬株式会社	エルロチニブを有効成分とする医薬錠剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6434574A (en) *	1987-07-30	1989-02-06	Mazda Motor	Full mold casting device
ATE446955T1 (de) *	1995-03-30	2009-11-15	Pfizer Prod Inc	Chinazolinone derivate
US5747498A (en) †	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
NZ508154A (en) *	1998-04-29	2003-07-25	Osi Pharm Inc	N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
YU13200A (sh)	1999-03-31	2002-10-18	Pfizer Products Inc.	Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk)	1999-11-11	2006-02-15	Осі Фармасьютікалз, Інк.	Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування

2004
- 2004-02-03 US US10/771,217 patent/US7148231B2/en not_active Expired - Lifetime
- 2004-02-11 ES ES04710031T patent/ES2314373T5/es not_active Expired - Lifetime
- 2004-02-11 MX MXPA05008598A patent/MXPA05008598A/es active IP Right Grant
- 2004-02-11 DK DK04710031.8T patent/DK1597239T4/da active
- 2004-02-11 BR BRPI0407520-0A patent/BRPI0407520A/pt not_active Application Discontinuation
- 2004-02-11 AU AU2004212067A patent/AU2004212067C1/en not_active Expired
- 2004-02-11 HR HRP20050707AA patent/HRP20050707B1/hr not_active IP Right Cessation
- 2004-02-11 CA CA2514977A patent/CA2514977C/en not_active Expired - Lifetime
- 2004-02-11 JP JP2005518421A patent/JP4456079B2/ja not_active Expired - Lifetime
- 2004-02-11 DE DE602004016628T patent/DE602004016628D1/de not_active Expired - Lifetime
- 2004-02-11 AT AT04710031T patent/ATE408605T1/de active
- 2004-02-11 SI SI200430902T patent/SI1597239T2/sl unknown
- 2004-02-11 KR KR1020057015068A patent/KR100797430B1/ko not_active Expired - Lifetime
- 2004-02-11 NZ NZ541500A patent/NZ541500A/en not_active IP Right Cessation
- 2004-02-11 CN CNB2004800043815A patent/CN100506803C/zh not_active Expired - Lifetime
- 2004-02-11 PT PT04710031T patent/PT1597239E/pt unknown
- 2004-02-11 PL PL378561A patent/PL225428B1/pl unknown
- 2004-02-11 RU RU2005128774/04A patent/RU2376294C2/ru active
- 2004-02-11 EP EP04710031.8A patent/EP1597239B2/en not_active Expired - Lifetime
- 2004-02-11 WO PCT/EP2004/001244 patent/WO2004072049A1/en not_active Ceased
2005
- 2005-07-28 IL IL169975A patent/IL169975A/en active IP Right Grant
- 2005-08-08 ZA ZA200506339A patent/ZA200506339B/en unknown
- 2005-08-18 CO CO05082094A patent/CO5601019A2/es not_active Application Discontinuation
- 2005-08-25 NO NO20053953A patent/NO330781B1/no unknown

Also Published As

Publication number	Publication date
US20040162300A1 (en)	2004-08-19
ZA200506339B (en)	2006-05-31
AU2004212067B2 (en)	2009-03-19
CN1751032A (zh)	2006-03-22
EP1597239B1 (en)	2008-09-17
HRP20050707B1 (hr)	2013-10-25
PT1597239E (pt)	2008-10-10
ES2314373T5 (es)	2022-10-11
JP2006521288A (ja)	2006-09-21
WO2004072049A1 (en)	2004-08-26
IL169975A (en)	2011-06-30
JP4456079B2 (ja)	2010-04-28
MXPA05008598A (es)	2005-11-04
US7148231B2 (en)	2006-12-12
AU2004212067A1 (en)	2004-08-26
PL225428B1 (pl)	2017-04-28
CO5601019A2 (es)	2006-01-31
HRP20050707A2 (en)	2006-07-31
DK1597239T4 (da)	2022-09-26
AU2004212067C1 (en)	2009-09-24
DE602004016628D1 (de)	2008-10-30
KR100797430B1 (ko)	2008-01-23
ATE408605T1 (de)	2008-10-15
NO330781B1 (no)	2011-07-18
CN100506803C (zh)	2009-07-01
NZ541500A (en)	2008-03-28
KR20050095898A (ko)	2005-10-04
EP1597239A1 (en)	2005-11-23
ES2314373T3 (es)	2009-03-16
RU2005128774A (ru)	2006-05-10
SI1597239T2 (sl)	2022-10-28
BRPI0407520A (pt)	2006-02-14
CA2514977A1 (en)	2004-08-26
PL378561A1 (pl)	2006-05-02
SI1597239T1 (sl)	2009-02-28
NO20053953L (no)	2005-08-31
RU2376294C2 (ru)	2009-12-20
CA2514977C (en)	2010-06-22
EP1597239B2 (en)	2022-07-20

Publication	Publication Date	Title
DK1597239T4 (da)	2022-09-26	Polymorf af {6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3e)
ATE419253T1 (de)	2009-01-15	Inhibitoren von thienopyridin- und furopyridinkinase
AP1434A (en)	2005-06-20	Stable polymorph of N-(3-Ethynylphenylamino) -6, 7-bis (2-methoxyethoxy) -4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof.
ATE554087T1 (de)	2012-05-15	Neue kinaseinhibitoren
DE60316013D1 (de)	2007-10-11	Heteroaryl-pyrimidinderivate als jak-inhibitoren
PL406680A1 (pl)	2014-03-31	Inhibitory kinaz tyrozynowych
UA84167C2 (ru)	2008-09-25	Производные хиназолина как ингибиторы тирозинкиназы, способ их получения (варианты), фармацевтическая композиция на их основе
EA200501333A1 (ru)	2006-06-30	5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
BR0316350A (pt)	2005-09-27	Diaminotriazóis úteis como inibidores de proteìna cinases
UA85593C2 (uk)	2009-02-10	Похідні хіназолінону як інгібітори parp
DE60214703D1 (de)	2006-10-26	Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
CY1111716T1 (el)	2015-10-07	Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων
ATE468336T1 (de)	2010-06-15	Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de)	2007-07-15	Zusammensetzungen brauchbar als protein-kinase- inhibitoren
TW200634012A (en)	2006-10-01	3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
DE602004011924D1 (de)	2008-04-03	Chinazoline derivate und ihre anwendung in der krebsbehandlung
WO2004063151A3 (en)	2004-12-09	Novel tyrosine kinase inhibitors
UA85394C2 (ru)	2009-01-26	Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
ATE396731T1 (de)	2008-06-15	Thiazole zur verwendung als inhibitoren von protein-kinasen
WO2004030620A3 (en)	2004-06-10	Novel tyrosine kinase inhibitors
MXPA05009151A (es)	2005-10-20	Inhibidores de cinasa heterociclica.
BRPI0409580A (pt)	2006-04-18	compostos de quinazolina
TW200740816A (en)	2007-11-01	P38 MAP kinase inhibitors and methods for using the same
DE602005027728D1 (de)	2011-06-09	Benzodiazepin-Derivate als ROCK-Kinasen Hemmer
WO2005097755A3 (de)	2006-03-09	Imidazolderivate als hemmer von tyrosinkinase